Company News Forthcoming on $PVCT CUP Success

I have garnered information describing the success of treating cancer-inflicted patients in Provectus' compassionate use (expanded access) program ("CUP"). The CUP allows doctors to utilize PV-10 much more frequently and freely in treating enrolled patients. Treated indications include certain breast cancers, basal cell carcinoma, squamous cell carcinoma, certain head and neck cancers, and melanoma. Management is planning to issue a PR detailing CUP results.

The percentage of the more than 75+ CUP patients who at this point are now cancer-free thanks to PV-10 is stunning; however, we require much more information to better or fully understand the scope of this success.